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Table.
Initial Randomization
Imatinib Rituximab
N randomized 35 37
Patients with less than 6 months follow-up 4 4
Evaluable patients 31 33
Signiﬁcant clinical response 10 (32%) 7 (21%)
Treatment success: SCR without crossover,
relapse or death at 6 months
6 (19%) 4 (12%)
Treatment failure at 6 months 26 (84%) 29 (88%)
No signiﬁcant clinical response (SCR)* 20 24
Crossover to the other arm* 22 20
Relapse or death* 3 7
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the rash showed lymphocytic interface dermatitis and
formation of multiple necrotic keratinocytes with resultant
separation at the dermal epidermal junction; ﬁndings
consistent with GVHD of the skin. When the rash started,
the patient was concomitantly on Sulfamethoxazole/
Trimethoprim for pneumocystis jirovecii prophylaxis and
was on broad spectrum antibiotics for suspected sepsis;
the rash however continued to progress despite stopping
these antibiotics two days after the rash appeared. A repeat
biopsy was performed to conﬁrm that GVHD is more likely
than a drug reaction and this again showed features of
GVHD. Short tandem repeat testing to evaluate for
chimerism failed to show that in the blood but showed 11%
donor cells in the skin biopsy. A diagnosis of GVHD was
made, IV steroids were starteddﬁve days after the rash
developeddwith a methylprednisolone bolus followed by
1mg/kg; this achieved mild improvement. Etanercept was
added after four days of steroids (25 mg subcutaneously
twice weekly for 8 doses) with further improvement.
Conclusions: GVHD post solid organ transplant as a diag-
nosis is often missed, because the presenting signs and
symptoms are nonspeciﬁc and the condition is rare. Prog-
nosis is in general poor and complications of pancytopenia
usually lead to the high mortality associated with this dis-
ease. There are no guidelines as to how to treat this condition
but careful intensiﬁcation (or withdrawal) of immunosu-
pression can potentially lead to successful control of this
disease process. We treated this patient with parenteral
steroids and added etanercept with a favorable outcome.
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Background: Cutaneous sclerosis (CS) occurs in 20% of pa-
tients (pts) with chronic graft-versus-host disease (cGVHD)
and can severely compromise patient mobility and quality
of life.
Methods: Prospective, multi-center, randomized, two-arm
phase II crossover trial of imatinib (200 mg daily by mouth,
provided by Novartis) and rituximab (375 mg/m2 intrave-
nously weekly x 4 doses, repeatable after 3 months, pro-
vided by Genentech) for treatment of CS at 11 institutions
within the Chronic GVHD Consortium (NCT01309997).
CS was deﬁned as sclerotic skin, morphea, myofascial
involvement or joint contractures diagnosed within the
past 18 months (a score of 2 in any area on the Vienna
Skin Score (VSS), or a score of 5 or less at the shoulders,
elbows, or wrists, or a score of 3 or less at the ankles on the
photographic range of motion (P-ROM)). The primary
endpoint was the signiﬁcant clinical response (SCR) rate at
6 months, deﬁned as a 2 or more point improvement on
the VSS without worsening elsewhere or a 1-2 point
improvement in the P-ROM scale without worsening else-
where. Crossover was allowed at 6 months if CS did not
improve, or earlier for CS progression or drug intolerance.
Treatment success was deﬁned as achievement of SCR at 6
months without crossing over to the second medication,
recurrence of malignancy or death. With 37 pts per arm,
SCR +/- 15% could be estimated.
Results: 72 pts were enrolled between March 2011 and June
2014, 35 randomized to imatinib and 37 to rituximab. The
median age was 56 years (range 19-77), 44% were female,
and all had organs other than skin involved with chronic
GVHD at study enrollment. The median time from cGVHD
onset to study enrollment was 1.0 year (range 0-3.8). 64 pts
are evaluable for the primary endpoint; 8 have less than 6
months of follow-up. SCR was observed in 10/31 (32%) pts
randomized to imatinib and 7/33 (21%) randomized to rit-
uximab. Among SCR pts, 4 imatinib and 3 rituximab pts
crossed over due to clinician-perceived lack of response
despite SCR. Treatment success occurred for 6 (19%) on the
imatinib arm and 4 (12%) on the rituximab arm.
Conclusion: SCR based on stringent objective improvement
in physical ﬁndings was seen in <35% at 6-months after
initial treatment with either imatinib or rituximab for CS, but
treatment success was <20%. These results support the need
for new therapies for CS.
